

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

August 24, 2018

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 23, 2018**

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-34236**

(Commission  
File Number)

**11-3054851**

(IRS Employer  
Identification No.)

**35 Wilbur Street**

**Lynbrook, NY**

(Address of principal executive  
offices)

**11563**

(Zip Code)

Registrant's telephone number, including area code: **516.593.7000**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

## Introductory Comment

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

## Item 7.01 Regulation FD Disclosure

Officers and representatives of the Company will present to various investors and stockholders beginning August 23, 2018 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

## Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

### Exhibit Description

#### No.

|      |  |
|------|--|
| 99.1 | Presentation materials to be used by officers and other representatives of the Company |
|------|--|

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 24, 2018

**BioSpecifics Technologies Corp.**

By: /s/ Thomas L. Wegman

Name: Thomas L. Wegman

Title: President

---

**EXHIBIT INDEX**

**Exhibit Description**

**No.**

|      |   |
|------|---|
| 99.1 | <u>Presentation materials to be used by officers and other representatives of the Company</u> |
|------|---|

---